{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:44:28Z","timestamp":1794552268878,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gut Pathog"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Parkinson\u2019s disease (PD) is the second most common neurodegenerative disease worldwide. Gut dysbiosis is hypothesized to cause PD; therefore, whether probiotics can be used as adjuvants in the treatment of PD is being actively investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>We performed a systematic review and meta-analysis to evaluate the effectiveness of probiotic therapy in PD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PUBMED\/MEDLINE, EMBASE, Cochrane, Scopus, PsycINFO and Web of Science databases were searched till February 20, 2023. The meta-analysis used a random effects model and the effect size was calculated as mean difference or standardized mean difference. We assessed the quality of the evidence using the Grade of Recommendations Assessment, Development and Evaluation (GRADE) approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eleven studies involving 840 participants were included in the final analysis. This meta-analysis showed high-quality evidence of improvement in Unified PD Rating Scale Part III motor scale (standardized mean difference [95% confidence interval]) (\u2212\u00a00.65 [\u2212\u00a01.11 to \u2212\u00a00.19]), non-motor symptom (\u2212\u00a00.81 [\u2212\u00a01.12 to \u2212\u00a00.51]), and depression scale (\u2212\u00a00.70 [\u2212\u00a00.93 to -0.46]). Moderate to low quality evidence of significant improvement was observed in gastrointestinal motility (0.83 [0.45\u20131.10]), quality of life (\u2212\u00a01.02 [\u2212\u00a01.66 to \u2212\u00a00.37]), anxiety scale (\u2212\u00a00.72 [\u2212\u00a01.10 to \u2212\u00a00.35]), serum inflammatory markers (\u2212\u00a05.98 [\u2212\u00a09.20 to \u2212\u00a02.75]), and diabetes risk (\u2212\u00a03.46 [\u2212\u00a04.72 to \u2212\u00a02.20]). However, there were no significant improvements in Bristol Stool Scale scores, constipation, antioxidant capacity, and risk of dyslipidemia. In a subgroup analysis, probiotic capsules improved gastrointestinal motility compared to fermented milk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Probiotic supplements may be suitable for improving the motor and non-motor symptoms of PD and reducing depression. Further research is warranted to determine the mechanism of action of probiotics and to determine the optimal treatment protocol.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13099-023-00536-1","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T15:03:14Z","timestamp":1678114994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Effect of probiotic supplementation on gastrointestinal motility, inflammation, motor, non-motor symptoms and mental health in Parkinson\u2019s disease: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"15","author":[{"given":"Jong Mi","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chorom","family":"Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"536_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.776847","volume":"9","author":"Z Ou","year":"2021","unstructured":"Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson\u2019s disease in 204 Countries\/Territories From 1990 to 2019. Front Public Health. 2021;9: 776847.","journal-title":"Front Public Health"},{"issue":"7","key":"536_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1017\/S1092852900013560","volume":"11","author":"LL Borek","year":"2006","unstructured":"Borek LL, Amick MM, Friedman JH. Non-motor aspects of Parkinson\u2019s disease. CNS Spectr. 2006;11(7):541\u201354.","journal-title":"CNS Spectr"},{"issue":"12","key":"536_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/jcm7120521","volume":"7","author":"K Skonieczna-\u017bydecka","year":"2018","unstructured":"Skonieczna-\u017bydecka K, Marlicz W, Misera A, Koulaouzidis A, \u0141oniewski I. Microbiome\u2014the missing link in the gut-brain axis: focus on its role in gastrointestinal and mental health. J Clin Med. 2018;7(12):521.","journal-title":"J Clin Med"},{"issue":"3","key":"536_CR4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5455\/jcmr.2022.13.03.07","volume":"13","author":"AZS As","year":"2022","unstructured":"As AZS, Gogu AE, Chita DS, Frecus CE, Mihai CM. Narrative review on therapeutic effects of dietary approach in neurological disorders. J Complement Med Res. 2022;13(3):33\u201341.","journal-title":"J Complement Med Res."},{"issue":"1","key":"536_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s13311-017-0598-8","volume":"15","author":"LM Cox","year":"2018","unstructured":"Cox LM, Weiner HL. Microbiota signaling pathways that influence neurologic disease. Neurotherapeutics. 2018;15(1):135\u201345.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"536_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/metabo11010029","volume":"11","author":"P Li","year":"2021","unstructured":"Li P, Killinger BA, Ensink E, Beddows I, Yilmaz A, Lubben N, et al. Gut microbiota dysbiosis is associated with elevated bile acids in Parkinson\u2019s disease. Metabolites. 2021;11(1):29.","journal-title":"Metabolites"},{"issue":"1","key":"536_CR7","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009381","volume":"2","author":"RL Mosley","year":"2012","unstructured":"Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE. Inflammation and adaptive immunity in Parkinson\u2019s disease. Cold Spring Harb Perspect Med. 2012;2(1): a009381.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"536_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/MCG.0b013e318269fdd5","volume":"46","author":"L Morelli","year":"2012","unstructured":"Morelli L, Capurso L. FAO\/WHO guidelines on probiotics: 10 years later. J Clin Gastroenterol. 2012;46:S1\u20132.","journal-title":"J Clin Gastroenterol"},{"issue":"12","key":"536_CR9","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1212\/WNL.0000000000003127","volume":"87","author":"M Barichella","year":"2016","unstructured":"Barichella M, Pacchetti C, Bolliri C, Cassani E, Iorio L, Pusani C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT. Neurology. 2016;87(12):1274\u201380.","journal-title":"Neurology"},{"issue":"7","key":"536_CR10","first-page":"289","volume":"21","author":"S Borzabadi","year":"2018","unstructured":"Borzabadi S, Oryan S, Eidi A, Aghadavod E, Daneshvar Kakhaki R, Tamtaji OR, et al. The effects of probiotic supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson\u2019s disease: a randomized, double-blind, PlaceboControlled Trial. Arch Iran Med. 2018;21(7):289\u201395.","journal-title":"Arch Iran Med"},{"key":"536_CR11","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.2147\/CIA.S106284","volume":"11","author":"D Georgescu","year":"2016","unstructured":"Georgescu D, Ancusa OE, Georgescu LA, Ionita I, Reisz D. Nonmotor gastrointestinal disorders in older patients with Parkinson\u2019s disease: is there hope? Clin Interv Aging. 2016;11:1601\u20138.","journal-title":"Clin Interv Aging"},{"issue":"12","key":"536_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244680","volume":"15","author":"A Ibrahim","year":"2020","unstructured":"Ibrahim A, Ali RAR, Manaf MRA, Ahmad N, Tajurruddin FW, Qin WZ, et al. Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson\u2019s disease: a randomised controlled trial. PLoS ONE. 2020;15(12): e0244680.","journal-title":"PLoS ONE"},{"key":"536_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.08.917","volume":"357","author":"B Michela","year":"2015","unstructured":"Michela B, Pacchetti C, Bolliri C, Cassani E, Iorio L, Pusani C, et al. Double blind, placebo-controlled trial of a fermented milk containing multiple probiotics strains and prebiotic fiber for constipation associated with parkinson\u2019s disease. J Neurol Sci. 2015;357: e260.","journal-title":"J Neurol Sci"},{"issue":"3","key":"536_CR14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.clnu.2018.05.018","volume":"38","author":"OR Tamtaji","year":"2019","unstructured":"Tamtaji OR, Taghizadeh M, Daneshvar Kakhaki R, Kouchaki E, Bahmani F, Borzabadi S, et al. Clinical and metabolic response to probiotic administration in people with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38(3):1031\u20135.","journal-title":"Clin Nutr"},{"issue":"5","key":"536_CR15","first-page":"e772","volume":"96","author":"AH Tan","year":"2021","unstructured":"Tan AH, Lim SY, Chong KK, Manap MA, Hor JW, Lim JL, et al. Probiotics for constipation in Parkinson disease: a randomized placebo-controlled study. Neurology. 2021;96(5):e772\u201382.","journal-title":"Neurology"},{"issue":"1","key":"536_CR16","first-page":"S433","volume":"35","author":"XD Yang","year":"2020","unstructured":"Yang XD, He XQ, Xu SQ, Qian VV, Zhang Y, Song YY, et al. Effect of Lactobacillus casei supplementation on clinical response, gut microbiota and faecal metabolites in patients with Parkinson\u2019s disease a randomized, double-blind, placebo-controlled trial. Mov Disord. 2020;35(1):S433.","journal-title":"Mov Disord"},{"key":"536_CR17","doi-asserted-by":"publisher","DOI":"10.54724\/lc.2022.e9","volume":"2","author":"SW Lee","year":"2022","unstructured":"Lee SW, Koo MJ. PRISMA 2020 statement and guidelines for systematic review and meta-analysis articles, and their underlying mathematics: life cycle committee recommendations. Life Cycle. 2022;2: e9.","journal-title":"Life Cycle"},{"issue":"1","key":"536_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):1\u201311.","journal-title":"Syst Rev"},{"key":"536_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JA Sterne","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"536_CR20","doi-asserted-by":"crossref","unstructured":"Sterne JA, Egger M, Moher D. Addressing reporting biases. Cochrane handbook for systematic reviews of interventions: Cochrane book series. 2008:297\u2013333.","DOI":"10.1002\/9780470712184.ch10"},{"issue":"11","key":"536_CR21","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jclinepi.2010.08.010","volume":"64","author":"R Fu","year":"2011","unstructured":"Fu R, Gartlehner G, Grant M, Shamliyan T, Sedrakyan A, Wilt TJ, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the effective health care program. J Clin Epidemiol. 2011;64(11):1187\u201397.","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"536_CR22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"key":"536_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:1\u201312.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"536_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41531-022-00327-6","volume":"8","author":"H Sun","year":"2022","unstructured":"Sun H, Zhao F, Liu Y, Ma T, Jin H, Quan K, et al. Probiotics synergized with conventional regimen in managing Parkinson\u2019s disease. NPJ Parkinsons Dis. 2022;8(1):62.","journal-title":"NPJ Parkinsons Dis"},{"key":"536_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.parkreldis.2022.08.022","volume":"103","author":"Y Du","year":"2022","unstructured":"Du Y, Li Y, Xu X, Li R, Zhang M, Cui Y, et al. Probiotics for constipation and gut microbiota in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2022;103:92\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"536_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2022.105397","volume":"100","author":"S Mehrabani","year":"2023","unstructured":"Mehrabani S, Khorvash F, Heidari Z, Tajabadi-Ebrahimi M, Amani R. The effects of synbiotic supplementation on oxidative stress markers, mental status, and quality of life in patients with Parkinson\u2019s disease: a double-blind, placebo-controlled, randomized controlled trial. J Funct Foods. 2023;100: 105397.","journal-title":"J Funct Foods"},{"issue":"5","key":"536_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.tins.2007.03.006","volume":"30","author":"A Bj\u00f6rklund","year":"2007","unstructured":"Bj\u00f6rklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007;30(5):194\u2013202.","journal-title":"Trends Neurosci"},{"key":"536_CR28","first-page":"9","volume":"70","author":"O Hornykiewicz","year":"2006","unstructured":"Hornykiewicz O. The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl. 2006;70:9\u201315.","journal-title":"J Neural Transm Suppl"},{"issue":"2","key":"536_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0006-8993(03)03354-7","volume":"989","author":"WJ Burke","year":"2003","unstructured":"Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson\u2019s disease pathogenesis. Brain Res. 2003;989(2):205\u201313.","journal-title":"Brain Res"},{"key":"536_CR30","volume-title":"Parkinson\u2019s disease: pathogenesis and clinical aspects","author":"A Kouli","year":"2018","unstructured":"Kouli A, Torsney KM, Kuan WL. Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson\u2019s disease: pathogenesis and clinical aspects. Brisbane: Codon Publications; 2018."},{"issue":"1","key":"536_CR31","doi-asserted-by":"publisher","first-page":"s32","DOI":"10.1007\/s100720300035","volume":"24","author":"G Micieli","year":"2003","unstructured":"Micieli G, Tosi P, Marcheselli S, Cavallini A. Autonomic dysfunction in Parkinson\u2019s disease. Neurol Sci. 2003;24(1):s32\u20134.","journal-title":"Neurol Sci"},{"issue":"21","key":"536_CR32","doi-asserted-by":"publisher","first-page":"11648","DOI":"10.1073\/pnas.1917597117","volume":"117","author":"RX Wang","year":"2020","unstructured":"Wang RX, Lee JS, Campbell EL, Colgan SP. Microbiota-derived butyrate dynamically regulates intestinal homeostasis through regulation of actin-associated protein synaptopodin. Proc Natl Acad Sci. 2020;117(21):11648\u201357.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"536_CR33","doi-asserted-by":"publisher","first-page":"bvz039","DOI":"10.1210\/jendso\/bvz039","volume":"4","author":"SS Ghosh","year":"2020","unstructured":"Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc. 2020;4(2):bvz039.","journal-title":"J Endocr Soc"},{"issue":"5","key":"536_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.neurobiolaging.2007.08.018","volume":"30","author":"M Letiembre","year":"2009","unstructured":"Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, et al. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging. 2009;30(5):759\u201368.","journal-title":"Neurobiol Aging"},{"key":"536_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.20517\/2347-8659.2015.28","volume":"3","author":"CD Rietdijk","year":"2016","unstructured":"Rietdijk CD, Wezel RJ, Garssen J, Kraneveld AD. Neuronal toll-like receptors and neuro-immunity in Parkinson\u2019s disease, Alzheimer\u2019s disease and stroke. Neuroimmunology and Neuroinflammation. 2016;3:27\u201337.","journal-title":"Neuroimmunology and Neuroinflammation."},{"key":"536_CR36","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/ncomms2534","volume":"4","author":"C Kim","year":"2013","unstructured":"Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, et al. Neuron-released oligomeric \u03b1-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562.","journal-title":"Nat Commun"},{"issue":"3","key":"536_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/glia.22437","volume":"61","author":"L Fellner","year":"2013","unstructured":"Fellner L, Irschick R, Schanda K, Reindl M, Klimaschewski L, Poewe W, et al. Toll-like receptor 4 is required for \u03b1-synuclein dependent activation of microglia and astroglia. Glia. 2013;61(3):349\u201360.","journal-title":"Glia"},{"key":"536_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fnins.2019.00369","volume":"13","author":"E Fitzgerald","year":"2019","unstructured":"Fitzgerald E, Murphy S, Martinson HA. Alpha-synuclein pathology and the role of the microbiota in Parkinson\u2019s disease. Front Neurosci. 2019;13:369.","journal-title":"Front Neurosci"},{"key":"536_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fneur.2017.00037","volume":"8","author":"CD Rietdijk","year":"2017","unstructured":"Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJ, Kraneveld AD. Exploring Braak\u2019s hypothesis of Parkinson\u2019s disease. Front Neurol. 2017;8:37.","journal-title":"Front Neurol"},{"issue":"5","key":"536_CR40","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","volume":"110","author":"H Braak","year":"2003","unstructured":"Braak H, R\u00fcb U, Gai WP, Del Tredici K. Idiopathic Parkinson\u2019s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110(5):517\u201336.","journal-title":"J Neural Transm"},{"key":"536_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00277","author":"D Parada Venegas","year":"2019","unstructured":"Parada Venegas D, De la Fuente MK, Landskron G, Gonz\u00e1lez MJ, Quera R, Dijkstra G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.00277.","journal-title":"Front Immunol"},{"issue":"1","key":"536_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41531-020-00144-9","volume":"7","author":"RD Markello","year":"2021","unstructured":"Markello RD, Shafiei G, Tremblay C, Postuma RB, Dagher A, Misic B. Multimodal phenotypic axes of Parkinson\u2019s disease. Npj Parkinsons Dis. 2021;7(1):6.","journal-title":"Npj Parkinsons Dis."},{"issue":"12","key":"536_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028032","volume":"6","author":"CB Forsyth","year":"2011","unstructured":"Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson\u2019s disease. PLoS ONE. 2011;6(12): e28032.","journal-title":"PLoS ONE"},{"issue":"4","key":"536_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123013","volume":"10","author":"O Rossi","year":"2015","unstructured":"Rossi O, Khan MT, Schwarzer M, Hudcovic T, Srutkova D, Duncan SH, et al. Faecalibacterium prausnitzii strain HTF-F and its extracellular polymeric matrix attenuate clinical parameters in DSS-induced colitis. PLoS ONE. 2015;10(4): e0123013.","journal-title":"PLoS ONE"},{"issue":"1","key":"536_CR45","doi-asserted-by":"publisher","first-page":"1826748","DOI":"10.1080\/19490976.2020.1826748","volume":"12","author":"M Lenoir","year":"2020","unstructured":"Lenoir M, Mart\u00edn R, Torres-Maravilla E, Chadi S, Gonz\u00e1lez-D\u00e1vila P, Sokol H, et al. Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3. Gut Microbes. 2020;12(1):1826748.","journal-title":"Gut Microbes"},{"issue":"6","key":"536_CR46","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3349\/ymj.2017.58.6.1083","volume":"58","author":"B-G Yang","year":"2017","unstructured":"Yang B-G, Hur KY, Lee M-S. Alterations in gut microbiota and immunity by dietary fat. Yonsei Med J. 2017;58(6):1083\u201391.","journal-title":"Yonsei Med J"},{"issue":"1","key":"536_CR47","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3349\/ymj.2018.59.1.4","volume":"59","author":"MY Yoon","year":"2018","unstructured":"Yoon MY, Yoon SS. Disruption of the gut ecosystem by antibiotics. Yonsei Med J. 2018;59(1):4\u201312.","journal-title":"Yonsei Med J"},{"issue":"2","key":"536_CR48","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.celrep.2019.12.078","volume":"30","author":"ME Goya","year":"2020","unstructured":"Goya ME, Xue F, Sampedro-Torres-Quevedo C, Arnaouteli S, Riquelme-Dominguez L, Romanowski A, et al. Probiotic Bacillus subtilis protects against \u03b1-Synuclein aggregation in C. elegans. Cell Reports. 2020;30(2):367-80 e7.","journal-title":"Cell Reports."},{"issue":"2","key":"536_CR49","first-page":"223","volume":"37","author":"PA Engen","year":"2015","unstructured":"Engen PA, Green SJ, Voigt RM, Forsyth CB, Keshavarzian A. The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota. Alcohol Res. 2015;37(2):223\u201336.","journal-title":"Alcohol Res"},{"issue":"4","key":"536_CR50","doi-asserted-by":"publisher","first-page":"518","DOI":"10.4014\/jmb.1205.05018","volume":"23","author":"L Rodes","year":"2013","unstructured":"Rodes L, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C, et al. Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol. 2013;23(4):518\u201326.","journal-title":"J Microbiol Biotechnol"},{"key":"536_CR51","volume":"3","author":"J Ghyselinck","year":"2021","unstructured":"Ghyselinck J, Verstrepen L, Moens F, Van Den Abbeele P, Bruggeman A, Said J, et al. Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson\u2019s disease. Int J Pharm. 2021;3: 100087.","journal-title":"Int J Pharm"},{"issue":"5","key":"536_CR52","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.18632\/aging.102927","volume":"12","author":"V Castelli","year":"2020","unstructured":"Castelli V, d\u2019Angelo M, Lombardi F, Alfonsetti M, Antonosante A, Catanesi M, et al. Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson\u2019s disease models. Aging. 2020;12(5):4641\u201359.","journal-title":"Aging"},{"key":"536_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.844242","volume":"9","author":"V Musazadeh","year":"2022","unstructured":"Musazadeh V, Roshanravan N, Dehghan P, Ahrabi SS. Effect of probiotics on liver enzymes in patients with non-alcoholic fatty liver disease: an umbrella of systematic review and meta-analysis. Front Nutr. 2022;9: 844242.","journal-title":"Front Nutr"},{"key":"536_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106397","volume":"183","author":"M Zarezadeh","year":"2022","unstructured":"Zarezadeh M, Musazadeh V, Faghfouri AH, Sarmadi B, Jamilian P, Jamilian P, et al. Probiotic therapy, a novel and efficient adjuvant approach to improve glycemic status: an umbrella meta-analysis. Pharmacol Res. 2022;183: 106397.","journal-title":"Pharmacol Res"},{"key":"536_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175069","volume":"928","author":"V Musazadeh","year":"2022","unstructured":"Musazadeh V, Zarezadeh M, Ghalichi F, Ahrabi SS, Jamilian P, Jamilian P, et al. Anti-obesity properties of probiotics; a considerable medical nutrition intervention: findings from an umbrella meta-analysis. Eur J Pharmacol. 2022;928: 175069.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"536_CR56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/10408398.2021.2004578","volume":"63","author":"M Zarezadeh","year":"2023","unstructured":"Zarezadeh M, Musazadeh V, Faghfouri AH, Roshanravan N, Dehghan P. Probiotics act as a potent intervention in improving lipid profile: an umbrella systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2023;63(2):145\u201358.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"7626","key":"536_CR57","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/bmj.39343.408449.80","volume":"335","author":"JP Ioannidis","year":"2007","unstructured":"Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007;335(7626):914\u20136.","journal-title":"BMJ"},{"issue":"Suppl 1","key":"536_CR58","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/nutrit\/nuy060","volume":"76","author":"MA Fernandez","year":"2018","unstructured":"Fernandez MA, Marette A. Novel perspectives on fermented milks and cardiometabolic health with a focus on type 2 diabetes. Nutr Rev. 2018;76(Suppl 1):16\u201328.","journal-title":"Nutr Rev"},{"issue":"1","key":"536_CR59","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.medici.2015.11.008","volume":"52","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Wu Y, Fei X. Effect of probiotics on glucose metabolism in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Medicina. 2016;52(1):28\u201334.","journal-title":"Medicina"}],"container-title":["Gut Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-023-00536-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13099-023-00536-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-023-00536-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T16:03:46Z","timestamp":1678118626000},"score":1,"resource":{"primary":{"URL":"https:\/\/gutpathogens.biomedcentral.com\/articles\/10.1186\/s13099-023-00536-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["536"],"URL":"https:\/\/doi.org\/10.1186\/s13099-023-00536-1","relation":{},"ISSN":["1757-4749"],"issn-type":[{"value":"1757-4749","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]},"assertion":[{"value":"19 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript has been read and approved by all the authors, and the requirements for authorship, as stated earlier in this document, have been met.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The publication has been approved by all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}